Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

cheplapharm arzneimittel gmbh. (0000010466) ziegelhof 24, greifswald, 17489 - clomethiazole - capsule, soft - 192mg - clomethiazole (0000533459) 192mg

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

ge healthcare buchler gmbh & co kg (0000003641) gieselweg 1, braunschweig, 38110 - sodium iodide (131 i) - capsule,hard - 37mbq to 5.55gbq - sodium iodide (131 i) (0007790263) 222gbq

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

glenwood gmbh (0000011526) arabellastrasse 17, bogenhausen, munich, 81925 - morphine sulfate - oral solution - 10mg/5ml - morphine sulfate (0000064313) 10mg

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

biokanol pharma gmbh (0000003726) kehler strasse 7, rastatt, 76437 - probenecid - tablets - 500mg - probenecid (0000057669) 500mg - probenecid

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

venus pharma gmbh (0000008606) am bahnhof 1-3, werne, 59368 - topotecan hydrochloride - ΚΟΝΙΣ ΓΙΑ ΕΝΑΙΩΡΗΜΑ ΠΡΟΣ ΕΓΧΥΣΗ - 4mg/vial - topotecan hydrochloride (8000001521) 4,34mg - topotecan

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

pharmaceutical trading co ltd (0000003066) 33 artemidos avenue, metropolitan court, larnaca, 6025 - diphenhydramine hydrochloride - cream - 2% - diphenhydramine hydrochloride (0000147240) 2g - diphenhydramine

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

pharmaceutical trading co ltd (0000003066) 33 artemidos avenue, metropolitan court, larnaca, 6025 - cytarabine - solution for injection - 100mg/ml - cytarabine (0000147944) 100mg - cytarabine

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

a.d.l. pharmaceutical productsline limited (0000010163) 12 agiou spyridonos str., aradippou, larnaca, 7102 - dexamethasone; nystatin; chlorhexidine hydrochloride - cream - (100000u.i/1mg/11.5mg)/g - dexamethasone (0000050022) 1mg; nystatin (0001400619) 100000iu; chlorhexidine hydrochloride (0003697425) 11,5mg - dexamethasone

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - Άλλα προϊόντα πεπτικής οδού και μεταβολισμού, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Παράγοντες για δερματίτιδα, εξαιρουμένων των κορτικοστεροειδών - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.